Rituximab as Second-Line Treatment in Anti-NMDAR Encephalitis after Herpes Simplex Encephalitis in Children.
Paula Carrascosa-GarcíaLidia Oviedo-MelgaresDavid Torres-FernándezDaniel Blázquez-GameroThaís ArmanguéSara Vila-BedmarLuis M PrietoConcepción Miranda-HerreroMar Santos-SebastiánElena María Rincón-LópezElisa Fernandez-CookePublished in: Indian journal of pediatrics (2022)
The long-term response of two infants with anti-N-methyl-D-aspartate receptor (anti-NMDAR) post herpes simplex encephalitis treated with rituximab is reported here. Rituximab may improve the course of the disease and should be considered early as second-line treatment. Data on the long-term effect of rituximab in B cell depletion and immunoglobulins levels in infants are needed.